retatrutide clinical trials latest Weight Loss Results:Trial Data and FDA Status Retatrutide Phase 3: TRIUMPH Program
Description
Alcohol use A patient with a history of excess alcohol use must be advised to stop consuming alcohol before starting GLP-1 receptor agonist therapy
The primary outcome was change in alcohol intake from baseline to follow-up
Food and Drug Administration has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, kidney failure, and death due to cardiovascular disease for adults living with type 2 diabetes and chronic kidney disease
The dual receptor advantage Semaglutide activates one receptor
